DE3583791D1 - Spiro-hydantoine fuer die behandlung von diabetischen komplikationen. - Google Patents

Spiro-hydantoine fuer die behandlung von diabetischen komplikationen.

Info

Publication number
DE3583791D1
DE3583791D1 DE8585307712T DE3583791T DE3583791D1 DE 3583791 D1 DE3583791 D1 DE 3583791D1 DE 8585307712 T DE8585307712 T DE 8585307712T DE 3583791 T DE3583791 T DE 3583791T DE 3583791 D1 DE3583791 D1 DE 3583791D1
Authority
DE
Germany
Prior art keywords
nitrogen
hydrogen
methine
alkyl
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8585307712T
Other languages
English (en)
Inventor
Christopher A Lipinski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of DE3583791D1 publication Critical patent/DE3583791D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DE8585307712T 1984-10-30 1985-10-25 Spiro-hydantoine fuer die behandlung von diabetischen komplikationen. Expired - Fee Related DE3583791D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1984/001767 WO1986002647A1 (en) 1984-10-30 1984-10-30 Spiro-heteroazolones for treatment of diabetes complications

Publications (1)

Publication Number Publication Date
DE3583791D1 true DE3583791D1 (de) 1991-09-19

Family

ID=22182314

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8585307712T Expired - Fee Related DE3583791D1 (de) 1984-10-30 1985-10-25 Spiro-hydantoine fuer die behandlung von diabetischen komplikationen.

Country Status (17)

Country Link
EP (1) EP0180421B1 (de)
JP (1) JPS61109789A (de)
KR (1) KR870000625B1 (de)
AT (1) ATE66228T1 (de)
AU (1) AU553839B2 (de)
DE (1) DE3583791D1 (de)
DK (1) DK166150C (de)
ES (1) ES8704168A1 (de)
FI (1) FI83322C (de)
GR (1) GR852606B (de)
HU (1) HU198051B (de)
IE (1) IE58287B1 (de)
IL (1) IL76855A0 (de)
PH (1) PH23491A (de)
PL (2) PL152316B1 (de)
PT (1) PT81382B (de)
WO (1) WO1986002647A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537892A (en) * 1983-09-14 1985-08-27 Alcon Laboratories, Inc. Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase
US4952694A (en) * 1988-07-27 1990-08-28 Pfizer Inc. Novel resolution process for racemic spiro-hydantoins
US5006657A (en) * 1988-07-27 1991-04-09 Pfizer Inc. Intermediates in a resolution process for racemic spiro hydantoins
US5037831A (en) * 1990-05-21 1991-08-06 American Home Products Corporation Spiro-isoquinoline-pyrrolidines and analogs thereof useful as aldose reductase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2449030A1 (de) * 1974-10-11 1976-05-20 Schering Ag Neue pyridin-derivate
CA1088945A (en) * 1976-10-18 1980-11-04 Pfizer Limited Hydantoin derivatives as therapeutic agents
US4147795A (en) * 1977-02-11 1979-04-03 Pfizer Inc. Hydantoin derivatives as therapeutic agents
US4283409A (en) * 1979-10-29 1981-08-11 Pfizer Inc. Imidazolone derivatives

Also Published As

Publication number Publication date
PL255978A1 (en) 1987-07-13
PT81382B (pt) 1987-11-30
FI83322C (fi) 1991-06-25
HUT40659A (en) 1987-01-28
PT81382A (en) 1985-11-01
DK495285D0 (da) 1985-10-29
PL152323B1 (en) 1990-12-31
FI862634A0 (fi) 1986-06-19
FI862634A (fi) 1986-06-19
PH23491A (en) 1989-08-16
EP0180421B1 (de) 1991-08-14
FI83322B (fi) 1991-03-15
GR852606B (de) 1986-03-04
AU4916485A (en) 1986-05-08
JPS61109789A (ja) 1986-05-28
DK166150C (da) 1993-08-09
PL152316B1 (en) 1990-12-31
IE58287B1 (en) 1993-08-25
KR860003262A (ko) 1986-05-21
ES548271A0 (es) 1987-03-16
ES8704168A1 (es) 1987-03-16
KR870000625B1 (ko) 1987-03-26
DK166150B (da) 1993-03-15
IE852695L (en) 1986-04-30
HU198051B (en) 1989-07-28
EP0180421A1 (de) 1986-05-07
WO1986002647A1 (en) 1986-05-09
IL76855A0 (en) 1986-02-28
DK495285A (da) 1986-05-01
AU553839B2 (en) 1986-07-31
ATE66228T1 (de) 1991-08-15

Similar Documents

Publication Publication Date Title
AU2246292A (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
ES2014385T3 (es) Composicion biocida.
ZA887978B (en) N-phenylalkylbenzamide fungicides
DE3583791D1 (de) Spiro-hydantoine fuer die behandlung von diabetischen komplikationen.
ES2059348T3 (es) Composicion farmaceutica para el tratamiento de cataratas.
ES8606295A1 (es) Un procedimiento para la preparacion de nuevas espiro-3-heteroazolidindionas.
CS38584A2 (en) Zpusob pripravy 5 (2 alkoxyfenyl) thiazolidindionu
ATE124259T1 (de) Thiazolidine-2,4-dione für die behandlung der hypertonie.
HUT54688A (en) Process for producing compounds utilizable for treating ulcus and pharmaceutical compositions containing them as active components
KR910011793A (ko) 살균 화합물
DE3362523D1 (en) Optically active imidazolylpropanol compounds, and their production and use
TR199901040A3 (tr) Fungisidal karisimlar
ES8303381A1 (es) Procedimiento para la fabricacion de un compuesto de fenil- 1,3-perhidrotiacina-4-ona, 2-substituida
ZA832445B (en) 4-(substituted alkyl)-n-(1,3-dithiolan-2-ylidene)aniline

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee